Prescription medications remain one of the most common causes of severe adverse reactions in clinical medicine, accounting for thousands of deaths annually in Canada. The urgent need for rigorous, scientific drug safety research has been clearly understood for decades, but lacked national coordination until the arrival of the Canadian Network for Observational Drug Effect Studies (CNODES), which today released its first report documenting progress towards its goal of creating a fully operational system for rapid assessment of adverse drug effects in Canada.
The Douglas Institute is proud to be one of the ten member organizations of MONTRÉAL WALKS for mental health.
MONTRÉAL WALKS for mental health is an annual event. In 2011, more than 800 people walked together as an effort to help destigmatize mental illness and collect funds to improve mental health services.
On October 14, join the Douglas Institute team, which our Executive Director, Lynne McVey, will also be part of.
Translating Cardiovascular Genome-wide Discoveries to Genomic Medicine
Perspective from the Framingham Heart Study
Dr. Christopher O'Donnell
Associate Director and Scientific Director of Genome Research, Framingham Heart Study
Senior Investigator, National Heart, Lung and Blood Institute
Associate Clinical Professor, Harvard Medical School
caroline [dot] alcaraz [at] mcgill [dot] ca ()